Literature DB >> 14504134

A structural model of agonist binding to the alpha3beta4 neuronal nicotinic receptor.

Valeria Costa1, Andrea Nistri, Andrea Cavalli, Paolo Carloni.   

Abstract

(alpha3)2(beta4)3 is the most abundant type of neuronal nicotinic ACh receptor (nAChR) mediating cholinergic actions on the autonomic nervous system. Studies to refine or devise drugs selectively acting on (alpha3)2(beta4)3 receptors would benefit from a detailed description of the hitherto unclear agonist-binding domain. The present study reports a three-dimensional model for the ligand-binding domain (LBD) of this receptor either in its unoccupied or agonist-bound conformation. The receptor model was based on the structure of the acetylcholine-binding protein (AChBP), and was obtained using molecular modelling techniques. ACh, nicotine and cytisine (full agonists), muscarine (a selective agonist of muscarinic ACh receptors) and the allosteric modulator eserine were docked into the binding pockets of the receptor model. Simulated agonist-receptor complexes were compared with the agonist-binding complex of the AChBP, as well as of the (alpha4)2(beta2)3 type of nAChR, which is the commonest in the brain. Agonist docking identified discrete amino-acid residues of the beta subunits important for pharmacological selectivity of nAChRs. The predicted affinity of muscarine for the nAChR was low, suggesting the present model to be suitable for effective discrimination of nicotinic agonist binding versus nonselective cholinergic binding. Furthermore, the current model outlined a potential binding site for the allosteric modulator eserine, the site of action of which has remained elusive. The present LBD model of the receptor in its free state provides a novel structural framework to interpret experimental observations and a useful template for future investigations to develop (alpha3)2(beta4)3-selective ligands.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504134      PMCID: PMC1574092          DOI: 10.1038/sj.bjp.0705498

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  59 in total

Review 1.  Molecular basis of the charge selectivity of nicotinic acetylcholine receptor and related ligand-gated ion channels.

Authors:  P J Corringer; S Bertrand; J L Galzi; A Devillers-Thiéry; J P Changeux; D Bertrand
Journal:  Novartis Found Symp       Date:  1999

2.  Anionic residue in the alpha-subunit of the nicotinic acetylcholine receptor contributing to subunit assembly and ligand binding.

Authors:  N Sugiyama; A E Boyd; P Taylor
Journal:  J Biol Chem       Date:  1996-10-25       Impact factor: 5.157

3.  Neuromuscular blocking agents: structure and activity.

Authors:  P Pauling; T J Petcher
Journal:  Chem Biol Interact       Date:  1973-06       Impact factor: 5.192

4.  Acetylcholine receptor channel imaged in the open state.

Authors:  N Unwin
Journal:  Nature       Date:  1995-01-05       Impact factor: 49.962

5.  [3H]Epibatidine binding to bovine adrenal medulla: evidence for alpha3beta4* nicotinic receptors.

Authors:  R Benjamin Free; Darrell L Bryant; Susan B McKay; Daniel J Kaser; Dennis B McKay
Journal:  Neurosci Lett       Date:  2002-01-25       Impact factor: 3.046

6.  Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors.

Authors:  C W Luetje; J Patrick
Journal:  J Neurosci       Date:  1991-03       Impact factor: 6.167

7.  Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates.

Authors:  D A Stauffer; A Karlin
Journal:  Biochemistry       Date:  1994-06-07       Impact factor: 3.162

8.  The crystal structure of acetylcholine chloride: a new conformation for acetylcholine.

Authors:  J K Herdklotz; R L Sass
Journal:  Biochem Biophys Res Commun       Date:  1970-08-11       Impact factor: 3.575

9.  Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine.

Authors:  A Schrattenholz; J Godovac-Zimmermann; H J Schäfer; E X Albuquerque; A Maelicke
Journal:  Eur J Biochem       Date:  1993-09-01

10.  alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release.

Authors:  S Luo; J M Kulak; G E Cartier; R B Jacobsen; D Yoshikami; B M Olivera; J M McIntosh
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

View more
  16 in total

1.  Computational modeling study of human nicotinic acetylcholine receptor for developing new drugs in the treatment of alcoholism.

Authors:  Zeng-Jian Hu; Li Bai; Yousef Tizabi; William Southerland
Journal:  Interdiscip Sci       Date:  2009-11-14       Impact factor: 2.233

2.  Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach.

Authors:  Bogdan Iorga; Denyse Herlem; Elvina Barré; Catherine Guillou
Journal:  J Mol Model       Date:  2005-12-22       Impact factor: 1.810

3.  The conformation of acetylcholine at its target site in the membrane-embedded nicotinic acetylcholine receptor.

Authors:  P T F Williamson; A Verhoeven; K W Miller; B H Meier; A Watts
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-07       Impact factor: 11.205

4.  Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors.

Authors:  Diego Rayes; María José De Rosa; Steven M Sine; Cecilia Bouzat
Journal:  J Neurosci       Date:  2009-05-06       Impact factor: 6.167

5.  Effect of novel negative allosteric modulators of neuronal nicotinic receptors on cells expressing native and recombinant nicotinic receptors: implications for drug discovery.

Authors:  Tatiana F González-Cestari; Brandon J Henderson; Ryan E Pavlovicz; Susan B McKay; Raed A El-Hajj; Aravinda B Pulipaka; Crina M Orac; Damon D Reed; R Thomas Boyd; Michael X Zhu; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2008-11-04       Impact factor: 4.030

6.  Selective blockade of nicotinic acetylcholine receptors by pimobendan, a drug for the treatment of heart failure: reduction of catecholamine secretion and synthesis in adrenal medullary cells.

Authors:  Yumiko Toyohira; Tatsuhiko Kubo; Miyabi Watanabe; Yasuhito Uezono; Susumu Ueno; Koji Shinkai; Masato Tsutsui; Futoshi Izumi; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-02-16       Impact factor: 3.000

Review 7.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

Review 8.  Gating of nicotinic ACh receptors: latest insights into ligand binding and function.

Authors:  Jerrel L Yakel
Journal:  J Physiol       Date:  2009-11-16       Impact factor: 5.182

Review 9.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

10.  Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors.

Authors:  Scott B Hansen; Palmer Taylor
Journal:  J Mol Biol       Date:  2007-03-31       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.